China competitive strategy for clearer market decisions

Navigate China’s fast-moving biopharma landscape with locally grounded intelligence and strategic insight that help you anticipate competitive change, identify emerging opportunities and threats, and act with confidence.

Connect with our Experts

Many global biopharma CI teams have a critical blind spot. We see China through a different lens.

China’s growing role across pharma is changing the competitive questions CI teams need to answer, and ignoring such a major source of innovation is a high-risk strategy.

China now accounts for around 40% of the world’s innovative pipeline, roughly half of FDA approvals derive from Chinese IND applications, and Chinese assets make up 30–50% of the pipeline across several next-generation modalities. That momentum has political backing too: in 2026, the Chinese government designated biomedicine a national “emerging pillar industry,” ranking it alongside aerospace as a top strategic priority.

The implications extend far beyond China. Developments there can have major consequences for clinical development programs, BD and licensing activity, and strategic decisions worldwide. Prescient gives global teams a clearer view by identifying the targets and fields that are emerging, spotting the programs showing real potential, and understanding what is moving - and at what risk.

Having already spent over 20 years working in China, our expanded China capabilities now give even deeper insight into both the pipeline, from what’s coming next to the BD, M&A and licensing opportunities and threats it brings, and the in-line landscape, where the competitive positioning of marketed products continues to evolve.

China must become part of the global CI model, because the signals shaping tomorrow’s pharmaceutical landscape may already be visible there. The question is whether your team is seeing them.

20+ years on the ground

An established Beijing presence and deep knowledge of the local biopharma environment.

500+ China-focused projects

Experience spanning launch strategy, BD and M&A, lifecycle management, generics, pipeline, and regulatory questions across multiple therapeutic areas.

~22k vetted China contacts

Expanded expert access across HCPs, KOLs, payers, regulatory contacts, C-suite executives, and pharma leaders.

Native-language intelligence

Mandarin-speaking expertise in China and across Prescient, supporting primary and secondary research in the local language.

China-specific data access

Access to local and premium sources including ChinaDrugTrials, ChiCTR, CDE, NextBiopharm by PharmCube, and WeChat monitoring.

AI-enabled monitoring

Proprietary AI support for sources including ChiCTR enables faster extraction, translation, and monitoring of publicly available China clinical trial information.

Latest thought leadership from the Prescient Commercial Strategy practice

As China's role across the pharmaceutical industry continues to grow, organisations need to understand how developments in the market could shape global strategy.

In our latest article, Ryan Caradonna explores why the China intelligence gap is becoming a growing competitive risk, including:

Deploy local capabilities that deliver deeper competitive insight

Understanding China requires the local capabilities to find the right signals, validate what they mean, and put them into strategic context. Prescient's China competitive strategy capabilities combine on-the-ground expertise, local intelligence sources, primary research, and technology to give teams a more complete and timely view of the market.

China competitive intelligence and monitoring

Build a more complete view of competitor, clinical, regulatory, policy, and market developments through sources designed for the realities of China’s information ecosystem.

The Prescient team combines Mandarin-language research, China-specific databases, WeChat monitoring, and AI-enabled clinical trial tracking to identify signals that global sources can miss and provide a more timely view of how the landscape is evolving.

Local primary intelligence

Go beyond the public record with targeted insight from stakeholders who understand the realities of the Chinese market.

Our in-market capabilities and expanded expert access connect teams with China-based HCPs, KOLs, payers, regulatory contacts, and industry leaders, helping validate emerging signals, close intelligence gaps, and uncover perspectives that can be difficult to access remotely.

Capture locally relevant scientific, competitor, and stakeholder developments from important Chinese medical meetings and congresses.

Our in-person coverage combines local-language expertise with primary intelligence and strategic synthesis, helping teams identify emerging data, stakeholder perspectives, and competitive signals and understand their implications for the broader landscape.

China congress intelligence

Understand what may be coming next and how the position of current market participants is changing.

Prescient integrates intelligence across local clinical development, policy, competitor, and market activity to provide deeper visibility into the pipeline landscape, including emerging BD and licensing opportunities and threats, and the evolving competitive positioning of marketed products.

Pipeline and competitive landscape insights


Prescient's proprietary AI solution

We’ve leveraged our internal 'Prescient Intelligence' AI capabilities and customized an in-house solution that is specifically focused on China’s public clinical trial registry.


Real-time clinical and regulatory intelligence

Prescient has gone further with the introduction of PharmCube to bring our clients critically important data from China that is usually publicly unavailable. Our investments in private databases offer additional, proprietary data specific to the China market.


Ready to turn strategy into measurable impact?

The life sciences landscape is full of complexity, but you don't have to navigate it alone. As your strategy-to-impact partner, we are here to help you see further, go deeper and deliver impact where it counts. 

Connect with our experts